Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(WBUR 90.9/CommonHealth [Boston, MA]) Jan 31, 2017 - An oncologist worries that rosy ads for new cancer drugs could raise the hopes of very vulnerable patients unrealistically.
(Los Angeles Times) Feb 3, 2017 - In June, pharmaceutical giant Genentech sent doctors a letter saying they should no longer prescribe a blockbuster drug called Tarceva to most patients suffering from lung cancer.
(Financial Times) Feb 9, 2017 - Investors lose billions as immunotherapies fall short of high expectations.
(Merck) Feb 3, 2017 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer.
(Forbes) Jan 30, 2017 - Trump says drug companies are "getting away with murder" on drug prices. But most of the ideas batted around for controlling drug pricing have serious flaws.
(MD Anderson Cancer Center) Feb 7, 2017 - Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
(TheStreet) Feb 2, 2017 - Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial but the drug is also now tied to three patient deaths from capillary leak syndrome.
(ASCO) Feb 1, 2017 - A growing number of patients with cancer are benefitting from research advances in immunotherapy, leading the American Society of Clinical Oncology (ASCO) to name immunotherapy as the Society’s advance of the year for a second year in a row. Released today, this year’s report, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer highlights the expanding role of immunotherapy.
(New York Times/Well blog) Feb 14, 2017 - Hair loss has long been considered an inevitable part of chemotherapy, and one of the most emotionally devastating aspects of cancer treatment. But advances in scalp-cooling technology, widely used in Europe to help chemotherapy patients keep their hair, may help the practice gain ground in the United States.
(ECCO) Jan 29, 2017 - Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.